This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Russell M. Hustead, MD
Kansas City, Mo

JAMA. 1984;251(17):2210.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

I wish to point out a possible error and source of confusion in the dosage of ethinyl estradiol recommended for the prophylaxis of postmenopausal osteoporosis. In Dr Wayne S. Maxson's¹ otherwise excellent answer to the question on "Osteoporosis, Estrogen Therapy, and Cystitis," he states that ethinyl estradiol may be given in a dosage of 0.05 mg/day (or 50 µg/day), and he implies that this dosage is equivalent to 0.625 mg/day of conjugated estrogens.

I would agree that 0.625 mg of conjugated estrogens is generally accepted to be the minimum amount necessary to protect against further postmenopausal bone loss; however, the equivalent dosage of ethinyl estradiol probably should be 0.005 mg/day (5 µg/day) and not 0.05 mg/ day.

The equivalent potency of the various estrogen preparations is difficult to assess. According to Leon Speroff, a well-recognized expert in the field of gynecologic endocrinology, and colleagues,² 0.625 mg . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?